Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Laboratory for Molecular Medicine, |
RCV004018150 | SCV004848582 | likely pathogenic | Primary dilated cardiomyopathy | 2021-09-21 | criteria provided, single submitter | clinical testing | The p.Lys11030GlufsX11 variant in TTN has not been previously reported in individuals with cardiomyopathy nor in large population studies. This variant is predicted to cause a frameshift, which alters the protein’s amino acid sequence beginning at position 11030 and leads to a premature termination codon 11 amino acids downstream. This alteration is then predicted to lead to a truncated or absent protein. TTN truncating variants encoded in constitutive exons (PSI >95%) have been found to be significantly associated with dilated cardiomyopathy (DCM) regardless of their position in titin (Roberts 2015 PMID:25589632, Schafer 2017 PMID:27869827). The p.Lys11030GlufsX11 variant is located in such a highly expressed exon in the I-band. In summary, although additional studies are required to fully establish its clinical significance, this variant meets criteria to be classified as likely pathogenic for autosomal dominant DCM. ACMG/AMP Criteria applied: PVS1, PM2_Supporting. |